Tvardi Therapeutics (NASDAQ:TVRD) Trading Down 0.9% - Here's Why

Key Points

• Tvardi Therapeutics' stock (NASDAQ:TVRD) experienced a decline of 0.9%, trading around $26.65, with an increase in trading volume.
• Analysts have set various target prices for Tvardi Therapeutics, with Piper Sandler leading at $78.00, while the average target price across firms is $64.25.
• The company reported a significant earnings miss, posting a loss of ($1.00) per share, compared to the consensus estimate of ($0.51).

Tvardi Therapeutics, Inc. (NASDAQ:TVRD - Get Free Report) was down 0.9% during mid-day trading on Thursday . The company traded as low as $25.54 and last traded at $26.65. Approximately 26,391 shares traded hands during trading, an increase of 18% from the average daily volume of 22,347 shares. The stock had previously closed at $26.88.

Analysts Set New Price Targets

A number of research analysts recently issued reports on TVRD shares. Piper Sandler started coverage on shares of Tvardi Therapeutics in a research report on Thursday, June 12th. They set an "overweight" rating and a $78.00 target price for the company. Wall Street Zen upgraded shares of Tvardi Therapeutics to a "hold" rating in a research report on Saturday, May 24th. Oppenheimer started coverage on shares of Tvardi Therapeutics in a research report on Wednesday, May 21st. They set an "outperform" rating and a $65.00 target price for the company. Cantor Fitzgerald started coverage on shares of Tvardi Therapeutics in a research report on Friday, July 11th. They set an "overweight" rating and a $52.00 target price for the company. Finally, Raymond James Financial assumed coverage on shares of Tvardi Therapeutics in a research report on Monday, July 14th. They set an "outperform" rating and a $62.00 target price for the company. Four equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $64.25.

Tvardi Therapeutics Stock Performance

The firm has a 50-day moving average price of $24.90.

Tvardi Therapeutics (NASDAQ:TVRD - Get Free Report) last released its quarterly earnings results on Thursday, August 14th. The company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.49). Tvardi Therapeutics had a negative return on equity of 565.83% and a negative net margin of 595.39%.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. JPMorgan Chase & Co. acquired a new position in shares of Tvardi Therapeutics during the 2nd quarter worth about $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Tvardi Therapeutics during the 2nd quarter valued at about $43,000. Headlands Technologies LLC purchased a new stake in Tvardi Therapeutics during the 2nd quarter valued at about $80,000. New York State Common Retirement Fund purchased a new stake in Tvardi Therapeutics during the 2nd quarter valued at about $92,000. Finally, Bank of America Corp DE purchased a new stake in Tvardi Therapeutics during the 2nd quarter valued at about $399,000. Institutional investors and hedge funds own 44.66% of the company's stock.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.